Expression of RBMS3 in Breast Cancer Progression

The aim of the study was to evaluate the localization and intensity of RNA-binding motif single-stranded-interacting protein 3 (RBMS3) expression in clinical material using immunohistochemical (IHC) reactions in cases of ductal breast cancer (in vivo), and to determine the level of RBMS3 expression at both the protein and mRNA levels in breast cancer cell lines (in vitro). Moreover, the data obtained in the in vivo and in vitro studies were correlated with the clinicopathological profiles of the patients. Material for the IHC studies comprised 490 invasive ductal carcinoma (IDC) cases and 26 mastopathy tissues. Western blot and RT-qPCR were performed on four breast cancer cell lines (MCF-7, BT-474, SK-BR-3 and MDA-MB-231) and the HME1-hTERT (Me16C) normal immortalized breast epithelial cell line (control). The Kaplan–Meier plotter tool was employed to analyze the predictive value of overall survival of RBMS3 expression at the mRNA level. Cytoplasmatic RBMS3 IHC expression was observed in breast cancer cells and stromal cells. The statistical analysis revealed a significantly decreased RBMS3 expression in the cancer specimens when compared with the mastopathy tissues (p < 0.001). An increased expression of RBMS3 was corelated with HER2(+) cancer specimens (p < 0.05) and ER(−) cancer specimens (p < 0.05). In addition, a statistically significant higher expression of RBMS3 was observed in cancer stromal cells in comparison to the control and cancer cells (p < 0.0001). The statistical analysis demonstrated a significantly higher expression of RBMS3 mRNA in the SK-BR-3 cell line compared with all other cell lines (p < 0.05). A positive correlation was revealed between the expression of RBMS3, at both the mRNA and protein levels, and longer overall survival. The differences in the expression of RBMS3 in cancer cells (both in vivo and in vitro) and the stroma of breast cancer with regard to the molecular status of the tumor may indicate that RBMS3 could be a potential novel target for the development of personalized methods of treatment. RBMS3 can be an indicator of longer overall survival for potential use in breast cancer diagnostic process.

[1]  Yuting Zhou,et al.  Disruption of RBMS3 suppresses PD-L1 and enhances antitumor immune activities and therapeutic effects of auranofin against triple-negative breast cancer. , 2022, Chemico-biological interactions.

[2]  P. Dzięgiel,et al.  Role of RBMS3 Novel Potential Regulator of the EMT Phenomenon in Physiological and Pathological Processes , 2022, International journal of molecular sciences.

[3]  Xiaosheng Wang,et al.  Identification of key tumor stroma-associated transcriptional signatures correlated with survival prognosis and tumor progression in breast cancer , 2022, Breast Cancer.

[4]  Douglas B. Craig,et al.  RNA binding protein RBMS3 is a common EMT effector that modulates triple-negative breast cancer progression via stabilizing PRRX1 mRNA , 2021, Oncogene.

[5]  R. Sitarz,et al.  Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review , 2021, Cancers.

[6]  B. Győrffy,et al.  Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer , 2021, Computational and structural biotechnology journal.

[7]  X. Zuo,et al.  LncRNA MEG3 regulates breast cancer proliferation and apoptosis through miR-141-3p/RBMS3 axis. , 2021, Genomics.

[8]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[9]  Xiaoxi Li,et al.  Tumor Suppressor Effect of RBMS3 in Breast Cancer , 2021, Technology in cancer research & treatment.

[10]  M. Simon,et al.  The tumor microenvironment , 2020, Current Biology.

[11]  Delong Meng,et al.  Increased expression of RBMS3 predicts a favorable prognosis in human gallbladder carcinoma , 2020, Oncology reports.

[12]  F. Marincola,et al.  The Tumor Microenvironment , 2016, Methods in Molecular Biology.

[13]  I. Witz,et al.  The Tumor Microenvironment , 2012 .

[14]  G. Tse,et al.  Molecular Classification of Breast Cancer. , 2019, Advances in anatomic pathology.

[15]  Yue Hu,et al.  The RNA binding protein RBMS3 inhibits the metastasis of breast cancer by regulating Twist1 expression , 2019, Journal of Experimental & Clinical Cancer Research.

[16]  Libing Song,et al.  Loss of RBMS3 Confers Platinum Resistance in Epithelial Ovarian Cancer via Activation of miR-126-5p/β-catenin/CBP signaling , 2018, Clinical Cancer Research.

[17]  Y. Ling,et al.  RBMS3 Inhibits the Proliferation and Metastasis of Breast Cancer Cells. , 2018, Oncology research.

[18]  D. Fearon,et al.  Stromal Cells in the Tumor Microenvironment. , 2018, Advances in experimental medicine and biology.

[19]  A. Piotrowska,et al.  Periostin expression in cancer-associated fibroblasts of invasive ductal breast carcinoma. , 2016, Oncology reports.

[20]  Tao Zhang,et al.  Low expression of RBMS3 and SFRP1 are associated with poor prognosis in patients with gastric cancer. , 2016, American journal of cancer research.

[21]  Xia Li,et al.  Comprehensive characterization of lncRNA-mRNA related ceRNA network across 12 major cancers , 2016, Oncotarget.

[22]  A. Piotrowska,et al.  Expression of EMT Markers SLUG and TWIST in Breast Cancer. , 2015, Anticancer research.

[23]  Songbin Fu,et al.  RBMS3 is a tumor suppressor gene that acts as a favorable prognostic marker in lung squamous cell carcinoma , 2015, Medical Oncology.

[24]  Peter T. Simpson,et al.  Molecular classification of breast cancer , 2014, Virchows Archiv.

[25]  Y. Lai,et al.  Rbms3, an RNA-binding protein, mediates the expression of Ptf1a by binding to its 3'UTR during mouse pancreas development. , 2012, DNA and cell biology.

[26]  Yan Li,et al.  Downregulation of RBMS3 is associated with poor prognosis in esophageal squamous cell carcinoma. , 2011, Cancer research.

[27]  Jorge S. Reis-Filho,et al.  Histological types of breast cancer: How special are they? , 2010, Molecular oncology.

[28]  E. Zepeda-Castilla,et al.  [Molecular classification of breast cancer]. , 2008, Cirugia y cirujanos.

[29]  B. Stefanovic,et al.  RNA-binding protein RBMS3 is expressed in activated hepatic stellate cells and liver fibrosis and increases expression of transcription factor Prx1. , 2007, Journal of molecular biology.

[30]  S. Tanaka,et al.  Cloning of a human gene closely related to the genes coding for the c-myc single-strand binding proteins. , 2000, Gene.

[31]  T. Niki,et al.  MSSP promotes ras/myc cooperative cell transforming activity by binding to c‐Myc , 2000, Genes to cells : devoted to molecular & cellular mechanisms.

[32]  J. Higginson,et al.  International Agency for Research on Cancer. , 1968, WHO chronicle.